99
Participants
Start Date
September 21, 2011
Primary Completion Date
January 1, 2027
Study Completion Date
January 1, 2032
AZD6244
AZD6244 orally (at recommended Ph2 dose) every 12 hours on continuous daily schedule for cycles of 28 days until unacceptable toxicity, patient withdrawal or PD
Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
National Institutes of Health Clinical Center, Bethesda
Cincinnati Children's Hospital Medical Center, Cincinnati
National Cancer Institute (NCI)
NIH